Id: 3526904 Primary Obesity Surgery Endoluminal 2 (Pose 2.0): An International Multicenter Prospective Trial With Plication Durability Assessment

Dayyeh, Barham K. Abu; Turró, Román; Maselli, Daniel B.; Bautista-Castaño, Inmaculada; Asokkumar, Ravishankar; Espinós, Jorge C.; Mata, Alfredo; Matar, Reem; Vargas, Eric J.; Jaruvongvanich, Veeravich; Storm, Andrew C.; Clark, Matthew; Grothe, Karen; Neto, Manoel Galvão; Nava, G

doi:10.1016/j.gie.2021.03.076

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another prospective multicenter study similiarly reported a %TBWL of 13.4%, 16.7%, 16.2%, and 14.17%, and 3, 6, 12, and 18 months. 67 At 12-month follow-up, 86% and 56% achieved ≥10% and ≥15% TBWL, respectively. There were no SAE reported.…”

Section: Endoscopic Sleeve Gastroplasty (Esg)mentioning

confidence: 89%

Endoscopic Treatment of GERD in Patients With Obesity

Ghazi

Rapaka

Dayyeh

2021

Foregut: The Journal of the American Foregut Society

Self Cite

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is one of the most common obesity-associated comorbidities. The increasing prevalence of obesity worldwide is expected to cause a concomitant increase in the prevalence of GERD. While laparoscopic Nissen fundoplication (LNF) remains the gold standard for the treatment of GERD, its efficacy in the setting of obesity is limited by a relatively high rate of post-procedural reflux recurrence. Currently, Roux-en-Y gastric bypass (RYGB) is the gold standard treatment for GERD in patients with obesity. However, despite its proven efficacy, it remains underutilized due to its cost, safety concerns, and patient acceptance. During the past 2 decades, endoscopic therapies have emerged as minimally invasive and safe alternatives for the management of GERD. While most studies assessed their outcomes in patients without obesity, recently published case reports offered a potential framework for their use in patients with obesity. In this article, we review the available endoscopic anti-reflux therapies (EART) and endoscopic bariatric therapies (EBT), with emphasis on their potential role in the management of GERD in patients with obesity.

show abstract

Section: Endoscopic Sleeve Gastroplasty (Esg)mentioning

confidence: 89%

Endoscopic Treatment of GERD in Patients With Obesity

Ghazi

Rapaka

Dayyeh

2021

Foregut: The Journal of the American Foregut Society

Self Cite

View full text Add to dashboard Cite

show abstract

“…The favorable weight loss outcomes were also demonstrated in a recent prospective, international, multicenter study. 21 The authors reported a %TBWL of 13.4% at 3 months, 16.7% at 6 months, 16.2% at 12 months, and 14.17% at 18 months, with 86 and 56% of patients achieving more than or equal to 10% and more than or equal to 15% TBWL at 12 months, respectively. There were no SAEs reported.…”

Section: Primary Obesity Surgery Endoluminalmentioning

confidence: 94%

“…3 Surgical sleeve gastrectomy compared with endoscopic sleeve gastroplasty. 21 lipid profile, and liver enzymes, and could potentially play a role in the treatment of NAFLD.…”

Section: Endoscopic Sleeve Gastroplastymentioning

confidence: 99%

Future of Metabolic Endoscopy

Ghazi

Vargas

Abboud

et al. 2022

Journal of Digestive Endoscopy

Self Cite

View full text Add to dashboard Cite

Obesity has been escalating as one of the worst public health epidemics. Conservative therapies including lifestyle modifications and weight loss medications have limited efficacy and long-term sustainability. Bariatric surgeries, although effective, remain underutilized due to their cost, safety concerns, and patient acceptance. In the past two decades, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as safe, effective, and less invasive options for the treatment of obesity and its comorbidities, with recent studies reporting favorable outcomes in terms of weight loss and metabolic parameters. This article reviews the major and newly developed EBMTs, with emphasis on their metabolic effects and potential use in the management of metabolic conditions.

show abstract

“…The POSE 2.0 utilizes the same IOP to create multiple full-thickness interrupted plications at the level of the gastric body while sparing the fundus and has a much more favorable safety profile [50,51]. POSE 2.0 demonstrates favorable weight loss outcomes in several trials in which TBWL for patients post POSE ranged between 15.7-17.3% at 6 months [50][51][52]. In a recent prospective multicenter trial, 41 subjects underwent POSE 2.0 and were assessed for weight loss…”

Section: Primary Obesity Surgery Endoluminal (Pose)mentioning

confidence: 99%

“…50 51 POSE 2.0 demonstrates favorable weight loss outcomes in several trials in which TBWL for patients post-POSE ranged between 15.7 and 17.3% at 6 months. 50 51 52 In a recent prospective multicenter trial, 41 subjects underwent POSE 2.0 and were assessed for weight loss and other outcomes, and were found to have %TBWL of 13.9, 17.3, and 17.5% at 3, 6, and 9 months, respectively. 50 New data from this trial show %TBWL of 15.7 ± 6.8%.…”

Section: Primary Obesity Surgery Endoluminalmentioning

confidence: 99%

Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Obesity is strongly associated with nonalcoholic fatty liver disease (NAFLD) as well as advanced forms of the disease such as steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. While lifestyle and diet modifications have been the cornerstone of treatment for NASH thus far, they are only effective for less than half of the patients. New endoscopic bariatric therapies (EBT) have already proved to be safe and effective for the treatment of obesity and type 2 diabetes mellitus, and may provide an intermediate, less invasive and cost-effective option for patients with NASH. In this review, we aim to describe the data and evidence as well as outline future areas of development for endobariatric therapies for treatment of NASH. In conclusion, EBTs present an effective and safe therapeutic modality for use in the growing pandemic of obesity related liver disease and should be further investigated with large scale trials in this patient population.

show abstract

Id: 3526904 Primary Obesity Surgery Endoluminal 2 (Pose 2.0): An International Multicenter Prospective Trial With Plication Durability Assessment

Cited by 3 publications

References 0 publications

Endoscopic Treatment of GERD in Patients With Obesity

Endoscopic Treatment of GERD in Patients With Obesity

Future of Metabolic Endoscopy

Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis

Contact Info

Product

Resources

About